Wilding JPH, Batterham RL, Calanna S, et al. - In adults with obesity, researchers performed this double-blind trial to ascertain if once-weekly semaglutide at a dose of 2.4 mg can reduce weight when taken as an adjunct to lifestyle intervention. A total of 1,961 adults with a body-mass index of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, were included. Participants were randomized, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. Findings revealed that sustained, clinically relevant reduction in body weight was conferred by 2.4 mg of semaglutide once weekly plus lifestyle intervention in participants with overweight or obesity. The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo.